From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences – The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in …

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences – The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead. Entitled "From the Margins," each person’s experience is deliberately written around the margins of the book in order to raise awareness of what it feels like to live on the periphery of society with a chronic or life-threatening disease.

"I had one foot in my cancer patient space and the other in my LGBTQ+ space," reads an excerpt from one of the participants, named Stewart. "But there was no space where I could talk about both those things and bring them close to each other."

Gilead teamed up with David Olusoga, a British historian and professor, to put the book together. "Throughout history and to this day, there are many people pushed to the margins of society where illness intertwines with social class, race, ethnicity, sexuality and poverty," he says. "They shouldn’t have to take it upon themselves to overcome societies prejudices and inequalities."

The book was published last September, and its unique format and important messages have earned significant media coverage and interest among the global patient and medical community.

The work is part of Gilead’s larger efforts to spotlight and address stigma, discrimination and other barriers to wellbeing and care; and ultimately, to improve health equity.

To read From the Margins, download a copy here.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Previous Article

CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.

Next Article

Cisco’s Sustainability 101: What Are Smart Grids?

Related Posts

‫ PSI Talent Management تستحوذ علىOPRA Psychology Group

تعمل مجموعة OPRA Psychology Group على تعزيز وجود PSI في منطقة آسيا والمحيط الهادئ، مما يوسع من البصمة العالمية لـ PSI وفريق من علماء النفس الصناعي / التنظيمي وخبراء في إدارة المواهب غلينديل، كاليفورنيا، 13 أكتوبر 2021 /PRNewswire/ — عززت وحدة أعمال إدارة المواهب في PSI موقعها الريادي في سوق حلول المواهب العالمية من خلال الاستحواذ على OPRA Psychology […]

Dante Labs Announces Appointment of Mark Van Oene to its Board of Directors to Support Operational Approach and Commercial Strategy

CAMBRIDGE, United Kingdom, Aug. 24, 2021 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Van Oene as a member of its Board of Directors. Mark is the Chief Operating Officer at Pacific Biosciences, a leading provider of high-quality sequencing solutions. “I’m so pleased to […]

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Archer Aviation Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ACHR

NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Archer Aviation Inc. (NYSE: ACHR) between September 17, 2021 and August 15, 2023, both dates inclusive (the “Class Period”), of the important November 20, 2023 lead plaintiff deadline. SO WHAT: If you […]